{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:14:31Z","timestamp":1789924471040,"version":"4.0.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11990-w","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:22:59Z","timestamp":1780561379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions"],"prefix":"10.1007","volume":"53","author":[{"given":"Samira","family":"Anvari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Naghinezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Shokati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Sobhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-3290","authenticated-orcid":false,"given":"Mahshid Akhavan","family":"Rahnama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"11990_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick BG, Gupta VA, Vertino PM, Boise LH (2019) Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol 10:1121","journal-title":"Front Immunol"},{"issue":"14","key":"11990_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146799","volume":"26","author":"S Wang","year":"2025","unstructured":"Wang S, Yang C, Chen L (2025) LSA-DDI: Learning stereochemistry-aware drug interactions via 3D feature fusion and contrastive cross-attention. International Journal of Molecular Sciences 26(14):6799. https:\/\/doi.org\/10.3390\/ijms26146799","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"11990_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s13755-025-00370-6","volume":"13","author":"Y Qian","year":"2025","unstructured":"Qian Y, Wang Q, Yin L, Lu AY (2025) CF-DTI: Coarse-to-fine feature extraction for enhanced drug-target interaction prediction. Health Inf Sci Syst 13(1):55. https:\/\/doi.org\/10.1007\/s13755-025-00370-6","journal-title":"Health Inf Sci Syst"},{"key":"11990_CR4","doi-asserted-by":"crossref","unstructured":"Dufva O et al (2020) Immunogenomic landscape of hematological malignancies, Cancer cell, vol. 38, no. 3, pp. 380\u2013399. e13","DOI":"10.1016\/j.ccell.2020.06.002"},{"key":"11990_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557157","author":"A Shokati","year":"2025","unstructured":"Shokati A, Sanjari-Pour M, Akhavan Rahnama M, Hoseinzadeh S, Vaezi M, Ahmadvand M (2025) Allogeneic CART progress: Platforms, current progress and limitations. Frontiers in Immunology. https:\/\/doi.org\/10.3389\/fimmu.2025.1557157","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"11990_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14656566.2024.2340738","volume":"25","author":"ZE Walton","year":"2024","unstructured":"Walton ZE, Frigault MJ, Maus MV (2024) Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Expert Opin Pharmacother 25(3):263\u2013279","journal-title":"Expert Opin Pharmacother"},{"issue":"22","key":"11990_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225657","volume":"14","author":"J Xiao","year":"2022","unstructured":"Xiao J et al (2022) Natural killer cells: A promising kit in the adoptive cell therapy toolbox. Cancers 14(22):5657","journal-title":"Cancers"},{"issue":"11","key":"11990_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-03067-8","volume":"42","author":"M Sanjary","year":"2025","unstructured":"Sanjary M, Shokati A, Rahnama MA, Khaseb S, Ahmadvand M (2025) Engineering adoptive cell therapy for solid tumors. Medical Oncology 42(11):500. https:\/\/doi.org\/10.1007\/s12032-025-03067-8","journal-title":"Medical Oncology"},{"issue":"19","key":"11990_CR9","doi-asserted-by":"publisher","first-page":"7424","DOI":"10.7150\/thno.101941","volume":"14","author":"R Lv","year":"2024","unstructured":"Lv R et al (2024) Revolutionizing cancer treatment: The emerging potential and potential challenges of in vivo self-processed CAR cell therapy. Theranostics 14(19):7424","journal-title":"Theranostics"},{"issue":"1","key":"11990_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan X-Y (2024) Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target therapy 9(1):175","journal-title":"Signal Transduct Target therapy"},{"key":"11990_CR11","doi-asserted-by":"crossref","unstructured":"Quatrini L, Della Chiesa M, Sivori S, Mingari MC, Pende D, Moretta L (2021) Human NK cells, their receptors and function. Eur J Immunol 51(7):1566\u20131579","DOI":"10.1002\/eji.202049028"},{"key":"11990_CR12","doi-asserted-by":"crossref","unstructured":"Liu Z et al (2025) Engineering natural killer cells for cancer immunotherapy. Cell Rep Phys Sci","DOI":"10.1016\/j.xcrp.2025.102681"},{"key":"11990_CR13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3389\/fimmu.2017.01194","volume":"8","author":"A Zingoni","year":"2017","unstructured":"Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A (2017) Natural killer cell response to chemotherapy-stressed cancer cells: role in tumor immunosurveillance. Front Immunol 8:1194","journal-title":"Front Immunol"},{"key":"11990_CR14","unstructured":"Ekren R (2024) Transcriptomic alterations of natural killer cells in multiple myeloma. Universit\u00e9 de Toulouse"},{"issue":"1","key":"11990_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/imr.12600","volume":"280","author":"DH Raulet","year":"2017","unstructured":"Raulet DH, Marcus A, Coscoy L (2017) Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells. Immunol Rev 280(1):93\u2013101","journal-title":"Immunol Rev"},{"issue":"6","key":"11990_CR16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","volume":"105","author":"I Prager","year":"2019","unstructured":"Prager I, Watzl C (2019) Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol 105(6):1319\u20131329","journal-title":"J Leukoc Biol"},{"key":"11990_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148111","volume":"14","author":"L Dumolard","year":"2023","unstructured":"Dumolard L, Aspord C, Marche PN, Macek Jilkova Z (2023) Immune checkpoints on T and NK cells in the context of HBV infection: landscape, pathophysiology and therapeutic exploitation. Front Immunol 14:1148111","journal-title":"Front Immunol"},{"issue":"7","key":"11990_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073587","volume":"22","author":"D B\u0119bnowska","year":"2021","unstructured":"B\u0119bnowska D et al (2021) Immunological prognostic factors in multiple myeloma. Int J Mol Sci 22(7):3587","journal-title":"Int J Mol Sci"},{"issue":"Pt 2","key":"11990_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.147657","volume":"328","author":"M Sun","year":"2025","unstructured":"Sun M et al (2025) The interplay between post-transcriptional RNA regulation and Wnt\/\u03b2-Catenin signaling in cancer: A review. Int J Biol Macromol 328(Pt 2):147657. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.147657","journal-title":"Int J Biol Macromol"},{"issue":"33","key":"11990_CR20","doi-asserted-by":"publisher","first-page":"7314","DOI":"10.2174\/0109298673309489240816063313","volume":"32","author":"Y Cheng","year":"2025","unstructured":"Cheng Y et al (2025) The investigation of Nf\u03bab inhibitors to block cell proliferation in OSCC cells lines. Curr Med Chem 32(33):7314\u20137326. https:\/\/doi.org\/10.2174\/0109298673309489240816063313","journal-title":"Curr Med Chem"},{"issue":"11","key":"11990_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells14110846","volume":"14","author":"O Sinha","year":"2025","unstructured":"Sinha O, Abhipsha S, Sen Santara S (2025) Power of memory: A natural killer cell perspective. Cells 14(11):846","journal-title":"Cells"},{"issue":"1","key":"11990_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev-immunol-101819-074948","volume":"39","author":"AM Mujal","year":"2021","unstructured":"Mujal AM, Delconte RB, Sun JC (2021) Natural killer cells: from innate to adaptive features. Annu Rev Immunol 39(1):417\u2013447","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"11990_CR23","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.3390\/ijms26125524","volume":"26","author":"A Smolarska","year":"2025","unstructured":"Smolarska A et al (2025) Cell-Based Therapies for Solid Tumors: Challenges and Advances. Int J Mol Sci 26(12):5524","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11990_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/immuno5010009","volume":"5","author":"E Boneva","year":"2025","unstructured":"Boneva E, Shivarov V, Ivanova M (2025) A concise review of the role of the NKG2D receptor and its ligands in cancer. Immuno 5(1):9","journal-title":"Immuno"},{"issue":"10","key":"11990_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009934","volume":"12","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J Immunother Cancer 12(10):e009934","journal-title":"J Immunother Cancer"},{"issue":"2","key":"11990_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020210","volume":"13","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M (2021) The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers 13(2):210","journal-title":"Cancers"},{"issue":"1","key":"11990_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00505-7","volume":"13","author":"J Lu","year":"2024","unstructured":"Lu J et al (2024) Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp Hematol Oncol 13(1):39","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"11990_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.31083\/j.fbl2803058","volume":"28","author":"W Cui","year":"2023","unstructured":"Cui W, Wang Z, Lv J, Qin Y, Shi H (2023) MDSCs: the key players in the formation of pre-metastatic niche. Front Biosci Landmark Ed 28(3):58","journal-title":"Front Biosci Landmark Ed"},{"key":"11990_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113993","volume":"157","author":"D Sun","year":"2023","unstructured":"Sun D, Li X, Nie S, Liu J, Wang S (2023) Disorders of cancer metabolism: The therapeutic potential of cannabinoids. Biomed Pharmacother 157:113993. https:\/\/doi.org\/10.1016\/j.biopha.2022.113993","journal-title":"Biomed Pharmacother"},{"key":"11990_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303605","volume":"14","author":"H Jia","year":"2023","unstructured":"Jia H, Yang H, Xiong H, Luo KQ (2023) NK cell exhaustion in the tumor microenvironment. Front Immunol 14:1303605","journal-title":"Front Immunol"},{"key":"11990_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529403","volume":"16","author":"H Jing","year":"2025","unstructured":"Jing H, Gao Y, Sun Z, Liu S (2025) Recent advances in novel tumor immunotherapy strategies based on regulating the tumor microenvironment and immune checkpoints. Front Immunol 16:1529403","journal-title":"Front Immunol"},{"issue":"9","key":"11990_CR32","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41423-021-00732-6","volume":"18","author":"C Zhang","year":"2021","unstructured":"Zhang C, Hu Y, Xiao W, Tian Z (2021) Chimeric antigen receptor-and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol 18(9):2083\u20132100","journal-title":"Cell Mol Immunol"},{"key":"11990_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707542","volume":"12","author":"MB Khawar","year":"2021","unstructured":"Khawar MB, Sun H (2021) CAR-NK cells: from natural basis to design for kill. Front Immunol 12:707542","journal-title":"Front Immunol"},{"key":"11990_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847008","volume":"13","author":"M Soldierer","year":"2022","unstructured":"Soldierer M et al (2022) Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies. Front Immunol 13:847008","journal-title":"Front Immunol"},{"issue":"1","key":"11990_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-025-03351-5","volume":"44","author":"E Yi","year":"2025","unstructured":"Yi E, Lee E, Park HJ, Lee HH, Yun SH, Kim HS (2025) A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells. J Exp Clin Cancer Res 44(1):1\u201320","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"11990_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, Chuvin N, Valladeau-Guilemond J, Depil S (2024) Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol 21(4):315\u2013331","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"11990_CR37","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.3390\/curroncol30050378","volume":"30","author":"SR Mucha","year":"2023","unstructured":"Mucha SR, Rajendram P (2023) Management and prevention of cellular-therapy-related toxicity: early and late complications. Curr Oncol 30(5):5003\u20135023","journal-title":"Curr Oncol"},{"key":"11990_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1574742","volume":"16","author":"S Balkhi","year":"2025","unstructured":"Balkhi S, Zuccolotto G, Di Spirito A, Rosato A, Mortara L (2025) CAR-NK cell therapy: promise and challenges in solid tumors. Front Immunol 16:1574742","journal-title":"Front Immunol"},{"issue":"S2","key":"11990_CR39","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1002\/sctm.21-0135","volume":"10","author":"S-J Lu","year":"2021","unstructured":"Lu S-J, Feng Q (2021) CAR-NK cells from engineered pluripotent stem cells: off-the-shelf therapeutics for all patients. Stem Cells Transl Med 10(S2):S10\u2013S17","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"11990_CR40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","volume":"19","author":"F Fang","year":"2022","unstructured":"Fang F et al (2022) Advances in NK cell production. Cell Mol Immunol 19(4):460\u2013481","journal-title":"Cell Mol Immunol"},{"key":"11990_CR41","unstructured":"Jo D-H (2025) Innovative Approaches to Natural Killer Cell Engineering: Overcoming Challenges in CRISPR-Cas9 Genome Editing. Transgene Expression, and Cryopreservation, Universit\u00e9 d\u2019Ottawa\/University of Ottawa"},{"key":"11990_CR42","doi-asserted-by":"publisher","first-page":"1275076","DOI":"10.3389\/fonc.2023.1275076","volume":"13","author":"SH Vu","year":"2023","unstructured":"Vu SH et al (2023) Adoptive NK Cell Therapy-a Beacon of Hope in multiple myeloma treatment. Front Oncol 13:1275076","journal-title":"Front Oncol"},{"issue":"3","key":"11990_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/fon-2021-1090","volume":"18","author":"LD Anderson Jr.","year":"2022","unstructured":"Anderson LD Jr. (2022) Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol 18(3):277\u2013289. https:\/\/doi.org\/10.2217\/fon-2021-1090","journal-title":"Future Oncol"},{"issue":"2","key":"11990_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD et al (2022) Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 12(2):32. https:\/\/doi.org\/10.1038\/s41408-022-00629-1","journal-title":"Blood Cancer J"},{"issue":"1","key":"11990_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G (2024) Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J 14(1):158. https:\/\/doi.org\/10.1038\/s41408-024-01139-y","journal-title":"Blood Cancer J"},{"key":"11990_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262211224","author":"A Bastrich","year":"2025","unstructured":"Bastrich A, Vinogradova K, Mokrousova D, Efremova A, Makhnach O, Goldshtein D (2025) State of the art of CAR-NK cell therapy in Multiple Myeloma: a comprehensive review of cell sources and target antigens. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms262211224","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11990_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2025.2546443","volume":"14","author":"K Schindler-Wnek","year":"2025","unstructured":"Schindler-Wnek K, Stahringer A, Heimer N, Koehl U, Fricke S, Schmiedel D (2025) Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies. OncoImmunology 14(1):2546443. https:\/\/doi.org\/10.1080\/2162402x.2025.2546443","journal-title":"OncoImmunology"},{"key":"11990_CR48","doi-asserted-by":"crossref","unstructured":"Nishida H (2021) Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review, Cancers, vol. 13, no. 11, p. 2712","DOI":"10.3390\/cancers13112712"},{"key":"11990_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010248","author":"E Park","year":"2024","unstructured":"Park E et al (2024) CAR NK92 cells targeting BCMA can effectively kill Multiple Myeloma cells both in vitro and in vivo. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12010248","journal-title":"Biomedicines"},{"key":"11990_CR50","doi-asserted-by":"crossref","unstructured":"Motais B, Charv\u00e1tov\u00e1 S, Walek Z, H\u00e1jek R, Bag\u00f3 JR (2023) NK92 expressing anti-BCMA CAR and secreted TRAIL for the treatment of multiple myeloma: preliminary in vitro assessment, Cells, vol. 12, no. 23, p. 2748","DOI":"10.3390\/cells12232748"},{"key":"11990_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110525","volume":"130","author":"A Xu","year":"2020","unstructured":"Xu A et al (2020) NF-\u03baB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomed Pharmacother 130:110525. https:\/\/doi.org\/10.1016\/j.biopha.2020.110525","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"11990_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-026-10104-z","volume":"26","author":"F Heydari","year":"2026","unstructured":"Heydari F et al (2026) Beyond remission: the cardiotoxic and thrombotic shadow of AML chemotherapy. Cardiovasc Toxicol 26(3):31. https:\/\/doi.org\/10.1007\/s12012-026-10104-z","journal-title":"Cardiovasc Toxicol"},{"key":"11990_CR53","doi-asserted-by":"crossref","unstructured":"Tojjari A, Giles FJ, Vilbert M, Saeed A, Cavalcante L (2023) SLAM modification as an immune-modulatory therapeutic approach in cancer, Cancers, vol. 15, no. 19, p. 4808","DOI":"10.3390\/cancers15194808"},{"key":"11990_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/hum.2023.128","volume":"34","author":"C Bonini","year":"2023","unstructured":"Bonini C et al (2023) Genome editing in engineered T cells for cancer immunotherapy. Hum Gene Ther 34:17\u201318","journal-title":"Hum Gene Ther"},{"key":"11990_CR55","doi-asserted-by":"crossref","unstructured":"O\u2019Neal J et al (2022) CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8\u2009+\u2009CS1 expressing CAR-T cells, Leukemia, vol. 36, no. 6, pp. 1625\u20131634","DOI":"10.1038\/s41375-022-01559-4"},{"issue":"1","key":"11990_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41416-018-0346-9","volume":"120","author":"K Kriegsmann","year":"2019","unstructured":"Kriegsmann K et al (2019) Cell-based immunotherapy approaches for multiple myeloma. Br J Cancer 120(1):38\u201344","journal-title":"Br J Cancer"},{"key":"11990_CR57","doi-asserted-by":"crossref","unstructured":"Karvouni M et al (2023) Challenges in \u03b1CD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide, Cytotherapy, vol. 25, no. 7, pp. 763\u2013772","DOI":"10.1016\/j.jcyt.2023.03.006"},{"key":"11990_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008769","author":"C Korst","year":"2024","unstructured":"Korst C et al (2024) Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-008769","journal-title":"J Immunother Cancer"},{"issue":"5","key":"11990_CR59","first-page":"265","volume":"48","author":"J Peter","year":"2025","unstructured":"Peter J, Toppeta F, Trubert A, Danhof S, Hudecek M, D\u00e4ullary T (2025) Multi-targeting CAR-T cell strategies to overcome immune evasion in lymphoid and myeloid malignancies. Oncol Res Treat 48(5):265\u2013279","journal-title":"Oncol Res Treat"},{"issue":"2","key":"11990_CR60","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11864-021-00920-6","volume":"23","author":"A Khurana","year":"2022","unstructured":"Khurana A, Lin Y (2022) Allogeneic chimeric antigen receptor therapy in lymphoma. Curr Treat Options Oncol 23(2):171\u2013187","journal-title":"Curr Treat Options Oncol"},{"key":"11990_CR61","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA et al (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. European Journal of Cancer 81:116\u2013129","journal-title":"European Journal of Cancer"},{"issue":"11","key":"11990_CR62","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14740338.2023.2274420","volume":"22","author":"S Midha","year":"2023","unstructured":"Midha S et al (2023) A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. Exp Opin Drug Saf 22(11):1049\u20131071","journal-title":"Exp Opin Drug Saf"},{"issue":"3","key":"11990_CR63","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D et al (2024) Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: a phase 1\/2 trial. Nat Med 30(3):772\u2013784. https:\/\/doi.org\/10.1038\/s41591-023-02785-8","journal-title":"Nat Med"},{"issue":"4","key":"11990_CR64","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW et al (2019) ASTCT consensus grading for Cytokine Release Syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"11990_CR65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10555-025-10273-3","volume":"44","author":"Y Deng","year":"2025","unstructured":"Deng Y et al (2025) Prospects and limitations of NK cell adoptive therapy in clinical applications. Cancer Metastasis Rev 44(3):57","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"11990_CR66","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40164-024-00583-7","volume":"13","author":"P Yao","year":"2024","unstructured":"Yao P, Liu Y-G, Huang G, Hao L, Wang R (2024) The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances. Exp Hematol Oncol 13(1):118","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"11990_CR67","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma S, Caligiuri MA, Yu J (2022) Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol 43(10):833\u2013847","journal-title":"Trends Immunol"},{"key":"11990_CR68","doi-asserted-by":"crossref","unstructured":"Li W, Wang X, Zhang X, Aziz AuR, Wang D (2024) CAR-NK cell therapy: a transformative approach to overcoming oncological challenges, Biomolecules, vol. 14, no. 8, p. 1035","DOI":"10.3390\/biom14081035"},{"key":"11990_CR69","doi-asserted-by":"crossref","unstructured":"Krug A, Martinez-Turtos A, Verhoeyen E (2021) Importance of T, NK, CAR T and CAR NK cell metabolic fitness for effective anti-cancer therapy: a continuous learning process allowing the optimization of T, NK and CAR-based anti-cancer therapies, Cancers, vol. 14, no. 1, p. 183","DOI":"10.3390\/cancers14010183"},{"issue":"6","key":"11990_CR70","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1021\/acsbiomaterials.4c01725","volume":"11","author":"P Guo","year":"2025","unstructured":"Guo P et al (2025) Nanomaterial-Interleukin Combination for Boosting NK Cell-Based Tumor Immunotherapy. ACS Biomaterials Sci Eng 11(6):3126\u20133144","journal-title":"ACS Biomaterials Sci Eng"},{"key":"11990_CR71","doi-asserted-by":"publisher","unstructured":"Naghinezhad J et al (2025) Smart DNA hydrogels for post-surgical hemostasis and tumor recurrence prevention: bridging bioengineering and clinical translation. Cancer Nanotechnol. https:\/\/doi.org\/10.1186\/s12645-025-00355-w","DOI":"10.1186\/s12645-025-00355-w"},{"key":"11990_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1625426","volume":"16","author":"M Niedzielska","year":"2025","unstructured":"Niedzielska M et al (2025) CAR-iNKT cells: redefining the frontiers of cellular immunotherapy. Front Immunol 16:1625426","journal-title":"Front Immunol"},{"issue":"4","key":"11990_CR73","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","volume":"19","author":"F Fang","year":"2022","unstructured":"Fang F et al (2022) Advances in NK cell production. Cell Mol Immunol 19(4):460\u2013481. https:\/\/doi.org\/10.1038\/s41423-021-00808-3","journal-title":"Cell Mol Immunol"},{"key":"11990_CR74","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jim.2018.09.012","volume":"463","author":"M Erdmann","year":"2018","unstructured":"Erdmann M et al (2018) Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy. J Immunol Methods 463:89\u201396. https:\/\/doi.org\/10.1016\/j.jim.2018.09.012","journal-title":"J Immunol Methods"},{"key":"11990_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1412378","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Byrne ME, Liu C, Ma MT, Liu D (2024) Scalable process development of NK and CAR-NK expansion in a closed bioreactor. Front Immunol 15:1412378. https:\/\/doi.org\/10.3389\/fimmu.2024.1412378","journal-title":"Front Immunol"},{"issue":"10","key":"11990_CR76","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1080\/21645515.2018.1480241","volume":"14","author":"Y Meng","year":"2018","unstructured":"Meng Y et al (2018) Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy. Hum Vaccin Immunother 14(10):2516\u20132526. https:\/\/doi.org\/10.1080\/21645515.2018.1480241","journal-title":"Hum Vaccin Immunother"},{"key":"11990_CR77","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.reth.2025.07.014","volume":"30","author":"T Kikuchi","year":"2025","unstructured":"Kikuchi T, Takeuchi I, Yamaguchi H (2025) Scalable production process development for NK cells targeting large-scale expansion. Regen Ther 30:535\u2013543. https:\/\/doi.org\/10.1016\/j.reth.2025.07.014","journal-title":"Regen Ther"},{"issue":"5","key":"11990_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004693","volume":"10","author":"S Maddineni","year":"2022","unstructured":"Maddineni S, Silberstein JL, Sunwoo JB (2022) Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. J Immunother Cancer 10(5):e004693","journal-title":"J Immunother Cancer"},{"key":"11990_CR79","doi-asserted-by":"crossref","unstructured":"Chang Y-J et al (2022) High-density cryopreservation of off-the-shelf CAR-NK cells facilitates on-demand treatment access, Blood, vol. 140, no. Supplement 1, pp. 4693\u20134","DOI":"10.1182\/blood-2022-162712"},{"key":"11990_CR80","doi-asserted-by":"crossref","unstructured":"Li T, Liu B, Dong C, Chang Y (2025) Cell Membrane Engineering for Advancing Cancer Immunotherapy. Cell Membrane Engineering for Advancing Cell-Based and Nanotechnology-Based Therapies. Springer, pp 305\u2013341","DOI":"10.1007\/978-3-031-93425-4_11"},{"key":"11990_CR81","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omto.2021.11.016","volume":"24","author":"A Poggi","year":"2022","unstructured":"Poggi A, Zocchi MR (2022) Natural killer cells and immune-checkpoint inhibitor therapy: current knowledge and new challenges. Mol Ther Oncolytics 24:26\u201342","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"11990_CR82","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.cell.2024.12.001","volume":"188","author":"X Wen","year":"2025","unstructured":"Wen X et al (2025) Evolutionary study and structural basis of proton sensing by Mus GPR4 and Xenopus GPR4. Cell 188(3):653-670.e24. https:\/\/doi.org\/10.1016\/j.cell.2024.12.001","journal-title":"Cell"},{"issue":"23","key":"11990_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315006","volume":"23","author":"K Sadowski","year":"2022","unstructured":"Sadowski K, Olejarz W, Basak G (2022) Modern advances in CARs therapy and creating a new approach to future treatment. Int J Mol Sci 23(23):15006","journal-title":"Int J Mol Sci"},{"key":"11990_CR84","doi-asserted-by":"crossref","unstructured":"Vera-Cruz S et al (2024) Cellular Therapies for Multiple Myeloma: Engineering Hope, Cancers, vol. 16, no. 22, p. 3867","DOI":"10.3390\/cancers16223867"},{"issue":"4","key":"11990_CR85","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-1087","volume":"14","author":"J Zhang","year":"2025","unstructured":"Zhang J et al (2025) From induced pluripotent stem cell (iPSC) to universal immune cells: literature review of advances in a new generation of tumor therapies. Transl Cancer Res 14(4):2495","journal-title":"Transl Cancer Res"},{"issue":"2","key":"11990_CR86","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10716","volume":"10","author":"N Dana","year":"2025","unstructured":"Dana N et al (2025) Advances in bioengineered CAR T\/NK cell therapy for glioblastoma: overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T\/NK cell therapy. Bioeng Transl Med 10(2):e10716","journal-title":"Bioeng Transl Med"},{"key":"11990_CR87","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jconrel.2024.07.067","volume":"373","author":"X Hao","year":"2024","unstructured":"Hao X et al (2024) Nanomaterials for bone metastasis. J Control Release 373:640\u2013651. https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.067","journal-title":"J Control Release"},{"key":"11990_CR88","doi-asserted-by":"crossref","unstructured":"Li J et al (2024) CAR-NK cells in combination therapy against cancer: a potential paradigm, Heliyon, vol. 10, no. 5","DOI":"10.1016\/j.heliyon.2024.e27196"},{"key":"11990_CR89","doi-asserted-by":"publisher","first-page":"0723","DOI":"10.34133\/research.0723","volume":"8","author":"A Lin","year":"2025","unstructured":"Lin A et al (2025) Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment. Research 8:0723","journal-title":"Research"},{"key":"11990_CR90","unstructured":"Karvouni M (2023) Cellular and personalized therapies in multiple myeloma with special emphasis on retargeted natural killer cells. Karolinska Institutet (Sweden)"},{"issue":"9","key":"11990_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092018","volume":"13","author":"FM Uckun","year":"2021","unstructured":"Uckun FM (2021) Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. Cancers 13(9):2018","journal-title":"Cancers"},{"key":"11990_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2025.109559","volume":"390","author":"X Wu","year":"2025","unstructured":"Wu X, Qin W, Tang S (2025) Analyzing the impact of threshold strategies on cancer treatment using non-smooth models. Math Biosci 390:109559. https:\/\/doi.org\/10.1016\/j.mbs.2025.109559","journal-title":"Math Biosci"},{"issue":"1","key":"11990_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03626-x","volume":"20","author":"Y Zhang","year":"2022","unstructured":"Zhang Y et al (2022) Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. J Transl Med 20(1):432","journal-title":"J Transl Med"},{"key":"11990_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1286491","volume":"14","author":"Z Peng","year":"2023","unstructured":"Peng Z et al (2023) Investigating the shared genetic architecture between hypothyroidism and rheumatoid arthritis. Front Immunol 14:1286491. https:\/\/doi.org\/10.3389\/fimmu.2023.1286491","journal-title":"Front Immunol"},{"issue":"7","key":"11990_CR95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011330","volume":"13","author":"LM Reindl","year":"2025","unstructured":"Reindl LM et al (2025) Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy. J Immunother Cancer 13(7):e011330","journal-title":"J Immunother Cancer"},{"issue":"2","key":"11990_CR96","doi-asserted-by":"publisher","DOI":"10.4110\/in.2025.25.e17","volume":"25","author":"B Marr","year":"2025","unstructured":"Marr B, Jo D, Jang M, Lee S-H (2025) Cytokines in focus: IL-2 and IL-15 in NK adoptive cell cancer immunotherapy. Immune Netw 25(2):e17","journal-title":"Immune Netw"},{"issue":"1","key":"11990_CR97","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13287-021-02251-7","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F et al (2021) Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Res Ther 12(1):200","journal-title":"Stem Cell Res Ther"},{"key":"11990_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1462307","volume":"11","author":"C Sainatham","year":"2024","unstructured":"Sainatham C et al (2024) The current socioeconomic and regulatory landscape of immune effector cell therapies. Front Med 11:1462307","journal-title":"Front Med"},{"key":"11990_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143687","author":"A Medina-Herrera","year":"2023","unstructured":"Medina-Herrera A, Sarasquete ME, Jim\u00e9nez C, Puig N, Garc\u00eda-Sanz R (2023) Minimal residual disease in multiple myeloma: past, present, and future. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15143687","journal-title":"Cancers (Basel)"},{"key":"11990_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1381212","volume":"15","author":"L Li","year":"2024","unstructured":"Li L, Sun Y, Luo J, Liu M (2024) Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis. Front Immunol 15:1381212. https:\/\/doi.org\/10.3389\/fimmu.2024.1381212","journal-title":"Front Immunol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11990-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11990-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11990-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:02:14Z","timestamp":1780567334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11990-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11990"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11990-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"During the development of this work, the authors used\n                      \n                      to speed up the process of finding the required articles and content for tables. After using this service, the authors reviewed and edited the content as needed, taking full responsibility for its content.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing\/Editorial Assistance"}}],"article-number":"885"}}